NFATc1 is necessary for remodeling endocardial cushions into mature heart valve leaflets and is also an essential effector of receptor activator of NFκB ligand (RANKL) signaling required for transcriptional activation of bone matrix remodeling enzymes during osteoclast differentiation. Therefore, developing heart valves were examined to determine if NFATc1 functions in the RANKL pathway during leaflet remodeling. Key components of RANKL signal transduction including RANKL, its receptor RANK, and the downstream remodeling enzyme cathepsin K (Ctsk) are expressed in the heart during valve remodeling and colocalize with NFATc1 in developing valve endocardium. However, the absence of tartrateresistant acid phosphatase (TRAP) activity and the lack of F4/80-positive macrophage lineage contribution to the remodeling valves demonstrate that certain aspects of osteoclast RANKL function are not shared during valve formation. Analysis of NFATc1
Introduction
Heart valve morphogenesis is a complex developmental process required for proper cardiac function, however, the molecular mechanisms that govern valve formation are incompletely understood. Heart valve development begins with the formation of valve precursors, termed endocardial cushions, in the outflow tract and atrioventricular canal (Schroeder et al., 2003; Wessels and Sedmera, 2003) . The cushions are formed from localized swellings of extracellular matrix that become populated by endocardial cells that have undergone an epithelial to mesenchymal transformation (EMT). Subsequently, the endocardial cushions are extensively remodeled to form the mature semilunar (aortic and pulmonary) and atrioventricular (mitral and tricuspid) valve leaflets (Barnett and Desgrosellier, 2003) . Whereas several molecular regulators of endocardial cushion formation and EMT have been identified (Person et al., 2005) , the mechanisms that control extracellular matrix remodeling during heart valve leaflet formation are not well defined.
The calcineurin/NFATc1 signaling pathway was among the first implicated in heart valve maturation with the observation that the endocardial cushions fail to remodel into valve leaflets in NFATc1 −/− mice (de la Pompa et al., 1998; Ranger et al., 1998) . Calcineurin, a serine/threonine phosphatase composed of a regulatory calcineurin B (CnB) subunit and a catalytic calcineurin A (CnA) subunit, is activated in response to sustained elevation of intracellular Ca 2+ levels (Klee et al., 1998) . Transcription factors of the NFATc family (c1-c4) are substrates of activated calcineurin that, upon dephosphorylation, translocate to the nucleus to regulate expression of target genes in cooperation with transcriptional cofactors (Crabtree and Olson, 2002; Hogan et al., 2003) . In mice, homozygous null mutation of NFATc1 or endothelial-specific deletion of Developmental Biology 292 (2006) 407 -417 www.elsevier.com/locate/ydbio calcineurin B results in lethality at approximately embryonic day (E)13.5 due to defects in valve formation (Chang et al., 2004; de la Pompa et al., 1998; Ranger et al., 1998) . Although endocardial cushion formation and EMT are initiated in both models, the semilunar and AV valves are hypoplastic and fail to remodel into mature leaflets (Chang et al., 2004; de la Pompa et al., 1998; Ranger et al., 1998) . Therefore, calcineurin/NFATc1 signaling during valve morphogenesis is not necessary for EMT (E8.5-E10.5) but is required for remodeling of the endocardial cushions into mature leaflets (E11+). In adult human pulmonary valve endothelial cells, calcineurin/NFATc1 signaling regulates cell proliferation in response to VEGF (Johnson et al., 2003) . The limited number of NFATc1 transcriptional targets in cardiac endothelial cells that have been identified includes the vasoconstrictor endothelin-1 (ET-1) and the calcineurin regulatory protein Down syndrome critical region 1 (DSCR1) (Lange et al., 2004; Nemer and Nemer, 2002) . Despite these advances, the mechanism by which NFATc1 regulates heart valve remodeling in relation to upstream activators and downstream transcriptional targets has remained elusive. In addition to its essential role in valve development, NFATc1 also is a critical transcriptional effector of RANKLmediated osteoclast differentiation (Hirotani et al., 2004; Ishida et al., 2002; Takayanagi et al., 2002) . RANKL, a member of the TNF ligand family, is a key factor for osteoclastogenesis and signals through its receptor RANK to promote differentiation of bone resorbing osteoclasts (Hsu et al., 1999; Lacey et al., 1998; Nakagawa et al., 1998) . RANKL signaling is negatively regulated by a soluble decoy receptor osteoprotegerin (OPG), which binds RANKL to prevent its interaction with RANK (Simonet et al., 1997; Yasuda et al., 1998a,b) . In addition to osteoclasts, the RANKL pathway also has roles in vascular endothelial cells as well as T-cells and dendritic cells of the immune system (Collin-Osdoby, 2004; Theoleyre et al., 2004; Walsh and Choi, 2003) . During osteoclast differentiation, RANKL strongly induces NFATc1 gene expression as well as sustained Ca 2+ oscillations necessary for calcineurin-mediated activation of NFATc1 protein (Day et al., 2004; Hirotani et al., 2004; Ishida et al., 2002; Takayanagi et al., 2002; Zhu et al., 2005) . Furthermore, osteoclast differentiation is impaired in NFATc1 deficient cells or by pharmacological inhibition of calcineurin activity, and expression of NFATc1 is sufficient to promote osteoclastogenesis in the absence of RANKL (Hirotani et al., 2004; Ikeda et al., 2004; Ishida et al., 2002; Matsuo et al., 2004; Takayanagi et al., 2002) . In addition, tartrate-resistant acid phosphatase (TRAP/Acp5) and the cysteine protease cathepsin K (Ctsk) are among the downstream targets of NFATc1 in differentiating osteoclasts (Ikeda et al., 2004; Matsumoto et al., 2004; Matsuo et al., 2004; Takayanagi et al., 2002) . While activators of NFATc1, including RANKL, and transcriptional targets, such as TRAP and Ctsk, have been defined in bone, this pathway has not been previously implicated in heart valve development. Therefore, to gain insight into the regulatory functions of NFATc1 in heart valve formation, the relationship between RANKL signaling and NFATc1 during valve leaflet remodeling was examined.
Materials and methods

Mice
NFATc1 gene targeted mice were obtained from Dr. Laurie Glimcher, and PU.1 heterozygous mice were a gift from Dr. Richard Lang (McKercher et al., 1996; Ranger et al., 1998) . Heterozygous intercrosses were established for timed matings with the presence of a copulation plug in the morning representing embryonic day (E)0.5. Genotypes were determined by PCR using yolk sac DNA as previously described (McKercher et al., 1996; Ranger et al., 1998) .
RT-PCR
Total RNA was isolated from whole E11.5-E14.5 hearts and E14.5 forelimbs using Trizol reagent (Life Technologies), and cDNA was generated with oligo(dT) primers and the SuperScript First-Strand Synthesis kit (Invitrogen). RT-PCR reactions for E11.5-E14.5 hearts were performed at 30 cycles. Quantitative real time RT-PCR was performed using the MJ Research Opticon Monitor II system. Real time RT-PCR analysis of Ctsk and Mmp2 gene expression in hearts from NFATc1 targeted mice was repeated three times using technical duplicates from three independent samples from each genotype. PCR reactions (95°C, 30 s; 64°C, 30 s; 72°C, 30 s; 35 cycles) included 0.1× Sybr Green (Molecular Probes), and fluorescence was monitored at 72°C. Gene expression levels were quantified based on threshold cycle [C(t)] calibrated to a standard curve and normalized to L7 as previously described (Lange et al., 2005) . Primer sequences and annealing temperatures are listed in Table 1 . Statistical significance of observed differences was determined by two-tailed Student's t test.
In situ hybridization
Sequences used to analyze gene expression by in situ hybridization were amplified by RT-PCR using E13.5 mouse heart cDNA, subcloned into pGEM T-vector (Promega), and confirmed by sequencing (see Table 1 ) or have been previously described (Lange et al., 2004) . Digoxigenin-labeled antisense RNA probes were generated from linearized plasmids using SP6 polymerase (Promega) or T7 polymerase (Roche). Embryos were isolated at E11.5-E14.5 and fixed overnight in 4% paraformaldehyde/PBS at 4°C. Forelimbs were dissected from E13.5 to E14.5 embryos and processed in parallel. After fixation, embryos and forelimbs were infiltrated with sucrose and embedded in OCT. Non-radioactive in situ hybridization was performed on cryosections (12-14 μm) as previously described (Lange et al., 2004) . Sections were mounted using Cytoseal (Electron Microscopy Science), and images were obtained using an Olympus BX60 microscope equipped with a Spot 3.0.4 digital camera.
Enzyme histochemistry
Mouse embryos were harvested at E13.5 or E15.5, rinsed in PBS, and snapfrozen unfixed in OCT for cryosectioning. Endogenous acid phosphatase or tartrate-resistant acid phosphatase enzyme activity was assessed on 7-10 μm sections using the leukocyte acid phosphatase kit (Sigma) according to the manufacturer's instructions. Counterstaining was omitted, and sections were mounted in aqueous media.
Immunofluorescence
Cryosections (5 μm) of fixed, OCT embedded embryos and forelimbs were used for immunofluorescent analysis of localized protein expression. Sections were rinsed in PBS to remove OCT, and microwave antigen retrieval was performed with Vector Unmasking Solution (Vector Labs) for NFATc1 or with 0.1 M glycine/PBS, pH 3.5 for Ctsk and F4/80. Sections were then rinsed in PBST (1× PBS, 0.1% Tween 20) and blocked for 1 h (2% serum from secondary antibody host species, 2% BSA, 0.1% NP-40). Primary antibody incubation was performed overnight at 4°C in blocking solution with mouse anti-NFATc1 (1:100, Santa Cruz), goat anti-cathepsin K (1:150, Santa Cruz), or rat anti-F4/80 (1:150, Abcam). Sections were then rinsed in PBST and incubated with secondary antibodies for 1 h at room temperature. Secondary antibodies were used at 1:200 in blocking solution and included goat anti-mouse Alexa Fluor 568, rabbit anti-goat Alexa Fluor 488, and goat anti-rat Alexa Fluor 488 (Molecular Probes). Following secondary antibody incubation, sections were rinsed and mounted with Vectashield Hard Set (Vector Labs). Fluorescent microscopy was performed using a Nikon PCM 2000 confocal microscope, and images were obtained with Simple PCI software.
Whole heart organ cultures
Whole heart organ cultures were established as described by Rentschler et al. (2002) . Nontransgenic or NFATc1 heterozygous intercrosses were established, and embryos were harvested at E10.5. Embryonic hearts were isolated and cultured in 24-well plates for 24 h at 37°C in DMEM containing 1% fetal bovine serum and penicillin/streptomycin (Gibco, 100 units/ml). Culture media was further supplemented with 100 ng/ml recombinant human RANKL (rhRANKL; R&D Systems) or 0.1% BSA for vehicle controls, and media was replaced at 12 h. All embryonic hearts obtained from NFATc1 heterozygous crosses were cultured in the presence of rhRANKL, and genotypes were determined by PCR using genomic DNA during the 24 h culture period. At 24 h, hearts were rinsed in PBS and two hearts from each experimental condition were pooled for RNA extraction as described above. Real time RT-PCR analysis was repeated six times using three independent pooled samples from each condition, and statistical significance was determined using a one-tailed Student's t test. Linear range RT-PCR was performed for NFATc1, Ctsk, and L7 (24, 30, and 22 cycles, respectively) gene expression in cultured hearts, and amplification products were analyzed on ethidium bromide gels. Alternatively, cultured hearts were fixed and embedded in OCT as previously described. Serial cryosections (5 μm) were analyzed by immunofluorescence for NFATc1 or in situ hybridization for NFATc1 and Ctsk as detailed above.
Results
Components of the RANKL signaling pathway are co-expressed in the remodeling heart valves Embryonic hearts were examined during early stages of heart valve remodeling for cardiac expression of genes associated with RANKL signal transduction. Transcripts for RANKL and its receptor RANK are detected in embryonic hearts between E11.5 and E14.5 by RT-PCR, demonstrating that genes involved in RANKL pathway activation are expressed in the developing heart (Fig. 1 ). In addition, embryonic hearts show strong expression of Ctsk, a potent matrix degrading protease and known target of RANKL signaling in osteoclasts, and Mmp2, an extracellular matrix metalloproteinase implicated in EMT during cushion formation ( Fig. 1) (Alexander et al., 1997; Song et al., 2000) . Notably, these genes are all expressed at significant levels in the heart at E13.5, a critical stage at which valve defects due to targeted inactivation of NFATc1 result in embryonic lethality (Chang et al., 2004; de la Pompa et al., 1998; Ranger et al., 1998) . Furthermore, expression of these genes in the developing forelimb (FL) at E14.5 corresponds to RANKL pathway function in osteoclast differentiation during bone formation. a Sequences amplified with these oligonucleotides were subcloned and used to generate antisense probes for in situ hybridization. Fig. 1 . Components of the RANKL pathway are expressed in the embryonic heart during stages of heart valve remodeling. Expression of genes in the RANKL signaling pathway was examined by RT-PCR of cDNA generated from E11.5-E14.5 mouse embryo whole hearts. RANKL, RANK, Ctsk, and Mmp2 gene expression is detected in embryonic hearts during early stages of valve remodeling. E14.5 forelimbs and no RT samples were included as positive and negative controls, respectively. L7 expression was included as a loading control. FL, forelimb.
The cardiac expression of RANKL-pathway-associated genes during heart valve development was further examined by in situ hybridization of embryo sections. Interestingly, these analyses revealed that RANKL, RANK, and Ctsk are coexpressed with NFATc1 in the developing atrioventricular and aortic valve endocardium of E13.5 hearts ( Fig. 2; arrowheads) . Fig. 2 . RANKL pathway genes are co-expressed in the developing heart valve endocardium and forelimb bone perichondrium. Localized expression of genes in the RANKL pathway was assessed by in situ hybridization in E13.5 hearts and E14.5 forelimbs. RANKL (A-C), RANK (D-F), NFATc1 (G-I), and Ctsk (J-L) are coexpressed in the endocardium of the developing aortic valves (A, D, G, J; arrowheads) and atrioventricular valves (B, E, H, K; arrowheads). RANK expression is also detected in the mesenchymal cells of the remodeling valves (D, E). In addition, co-expression is observed in the perichondrium of E14.5 forelimbs (C, F, I, L; arrows). AoV, aortic valves; AVV, atrioventricular valves; c, chondrocytes.
While RANKL, NFATc1, and Ctsk expression is predominant in endocardial cells, expression of the receptor RANK is also apparent in the transformed mesenchymal cells of the developing valves (Figs. 2D, E) . Consistent with the role of RANKL signaling in bone formation, expression of RANKL, RANK, NFATc1, and Ctsk is observed in the developing bone perichondrium of E14.5 forelimbs (Figs. 2C, F, I , L; arrows). In the developing limbs, these genes are expressed in a subset of cells surrounding the hypertrophic chondrocytes, a site that is associated with ossification and osteoclast differentiation later in development. Although expression of OPG was detected in the aortic vasculature by in situ hybridization of sections from E13.5 embryos, it was not observed in the developing heart valves or bones (data not shown). In the heart, co-expression of RANKL, RANK, NFATc1, and Ctsk was observed at all stages valve formation examined (E11.5-E14.5) and in all developing valve leaflets (pulmonary, aortic, mitral, and tricuspid) (data not shown). In developing skeletal elements, expression of these genes is first detected in the developing ribs and forelimbs at E12.5 and E13.5, respectively (data not shown). Together, these data demonstrate that components of RANKL signal transduction are co-expressed in developing bones and heart valves.
Heart valves express acid phosphatase but do not exhibit TRAP activity or macrophage lineage derivation characteristic of bone osteoclasts
Since RANKL pathway genes are expressed in colocalized patterns during formation of the heart valves and bones, further analysis was performed to determine the extent of the similarity between the two developing systems. A defining characteristic of differentiated bone osteoclasts is the presence of TRAP enzymatic activity. Histochemical analysis for general, nonspecific acid phosphatase enzyme activity and TRAP activity was performed in parallel on E13.5 and E15.5 embryo sections. Remodeling valves possess non-specific acid phosphatase activity comparable to that observed in the developing bones (Figs. 3A, C and data not shown). The presence of acid phosphatase activity in the developing valves is indicative of a low pH environment in the remodeling leaflets, an established requirement for bone matrix remodeling (Baron et al., 1985; Karsdal et al., 2005) . However, TRAP-positive cells are not detected in the heart valves and are only observed in developing bones including the ribs and forelimbs beginning at E15.5 (Figs. 3B, D and data not shown).
Since RANKL promotes differentiation of bone osteoclasts by inducing NFATc1 in precursor cells derived from macrophages, the contribution of macrophages to the embryonic heart valves was examined. The presence of macrophage cells was assessed by immunofluorescent antibody staining for the macrophage-specific surface antigen F4/80, which is first detected in the developing embryo at E10 (Morris et al., 1991) . In developing bones of the forelimb, F4/80-positive cells are observed along with NFATc1 and Ctsk-expressing cells in the pre-osteoclast population in the perichondrium at E13.5, consistent with the contribution of the macrophage lineage to osteoclast formation (Figs. 4B, D, F; arrows) . In contrast, F4/80-positive cells are not detected in the heart at E10.5, indicating that macrophages do not contribute to the early stages of valve formation when NFATc1 is apparent in developing valve endothelial cells (data not shown) (Ranger et al., 1998) . During heart valve remodeling, F4/80-positive macrophages are still not present in the heart of E13.5 embryos in association with valve endocardial cells expressing NFATc1 and Ctsk (Figs. 4A, C, E ).
To further demonstrate the lack of macrophage lineage contribution to the remodeling valves, hearts from PU.1 −/− embryos were examined. Homozygous null mutation of PU.1 results in the failure to establish the macrophage lineage evidenced by lack of F4/80 expression (Fig. 4H) (McKercher et al., 1996) . Despite macrophage lineage deficiency, valve leaflet formation and expression of RANKL, RANK, NFATc1, and Ctsk appear normal in E13.5 PU.1 −/− embryos ( Fig. 4J  and data not shown) . Thus, macrophage cells are not normally detected in the heart during early stages of valve formation, and their absence does not affect gene expression in the remodeling leaflet. The consistent absence of F4/80 expressing cells in the developing valves along with unaltered gene expression in hearts of macrophage deficient PU.1 −/− embryos demonstrates that valve endocardial expression of RANKL pathway genes is not dependent on the presence of macrophages. Together, these data show that macrophage lineage progenitors and TRAP activity are distinct characteristics of bone osteoclasts that are not associated with the presence of the RANKL system in the developing heart valves. 
Expression of RANKL and Ctsk in the developing heart valves is dependent on NFATc1
The requirement of NFATc1 for endocardial expression of RANKL pathway genes during heart valve remodeling was examined using NFATc1 −/− embryos. In situ hybridization of sections from E12.5 embryos shows that Ctsk expression is notably decreased in the developing valves of NFATc1 −/− hearts relative to control littermates, consistent with direct transcriptional regulation of Ctsk by NFATc1 (Figs. 5C, D; arrowheads) (Matsumoto et al., 2004) . Interestingly, expression of RANKL in the developing valves of homozygous NFATc1 null hearts is also visibly reduced compared to control hearts, suggesting that NFATc1 contributes to cardiac expression of RANKL (Figs. 5A,  B; arrowheads) . A variable reduction in Ctsk and RANKL gene expression was also observed in the perichondrium of the developing rib and forelimb bones of E12.5-E13.5 NFATc1 −/− embryos (data not shown). As a control, expression of Mmp2 was examined to determine if expression of a gene independent from the RANKL pathway is affected by loss of NFATc1. Consistent with its reported contribution to EMT (Alexander et al., 1997; Song et al., 2000) , Mmp2 is expressed in both the endocardium and mesenchyme of developing valves. Notably, Mmp2 expression in the valves is not overtly affected in NFATc1 −/− hearts (Figs. 5E, F) , indicating that the reduced expression of Ctsk and RANKL in NFATc1 −/− hearts is not due to a generalized loss of gene expression during valve formation in null embryos. Furthermore, unaltered expression of Mmp2 in NFATc1 deficient hearts is consistent with normal progression of EMT in NFATc1 −/− embryos (de la Pompa et al., 1998; Ranger et al., 1998) . Decreased expression of RANKL and Ctsk along with unaltered Mmp2 expression was equally apparent in the semilunar and the atrioventricular valves of E12.5-E13.5 NFATc1 −/− embryos (data not shown). In accordance with the results obtained by in situ hybridization, quantitative real time RT-PCR also shows that Ctsk expression is significantly decreased in whole hearts from E12.5 NFATc1 −/− embryos relative to wild-type or heterozygous controls, whereas cardiac expression of Mmp2 is unchanged between genotypes (Fig. 5G) . In addition to decreased Ctsk transcript levels, a clear reduction in Ctsk protein is also detected in valve endothelial cells of NFATc1 −/− hearts. In NFATc1 +/+ hearts, punctate intracellular Ctsk protein expression is detected in NFATc1-expressing endocardial cells of the developing tricuspid valve (Figs. 5H, J) . In contrast, loss of NFATc1 expression in homozygous null embryos results in a concomitant loss of endocardial Ctsk expression (Figs. 5I, K) .
Together, these results demonstrate that expression of RANKL and Ctsk in the developing valve endocardium is dependent on NFATc1 and suggest that regulation of valve leaflet remodeling by NFATc1 involves transcriptional activation of matrix degrading enzymes including Ctsk.
RANKL treatment affects NFATc1 and Ctsk gene expression in whole heart organ cultures
In order to gain insight into the effect of RANKL on cardiac expression of NFATc1 and Ctsk during heart valve development, isolated whole hearts from E10.5 embryos were maintained in organ culture for 24 h in the presence or absence of rhRANKL. Quantitative real time RT-PCR reveals elevated NFATc1 and Ctsk expression levels in hearts from normal embryos cultured in the presence of RANKL relative to vehicle control treated hearts (Fig. 6A) . In contrast, Mmp2 expression is not affected by rhRANKL treatment (Fig. 6A) , demonstrating that the augmented expression of NFATc1 and Ctsk is a specific response to RANKL treatment. Thus, RANKL can stimulate expression of NFATc1 and Ctsk in the heart during early stages of heart valve development. Hearts isolated from NFATc1 −/− embryos were cultured in the presence of RANKL to determine the requirement of NFATc1 in RANKL-mediated induction of Ctsk. Although a low level of NFATc1 transcripts is still detected in hearts from NFATc1 homozygous null embryos, these transcripts are not translated (see Fig. 5I ). Notably, Ctsk expression is significantly reduced in cultured NFATc1 −/− hearts despite treatment with RANKL (Fig. 6A) . In comparison, Mmp2 expression levels are not significantly altered in RANKLtreated hearts from NFATc1 deficient embryos (Fig. 6A) . Linear range RT-PCR was also performed for NFATc1, Ctsk, and L7 and was used to visualize increased NFATc1 and Ctsk expression in the presence of RANKL as well as decreased gene expression in RANKL-treated NFATc1 −/− cultured hearts (Fig. 6B) .
In situ hybridization of serial sections from cultured hearts further corroborates the observed effects of RANKL treatment on NFATc1 and Ctsk gene expression. Augmented expression of NFATc1 is detected in the outflow tract cushions of hearts treated with RANKL compared to a vehicle control heart (Figs. 6E, F; arrowheads). Furthermore, RANKL treatment induced occasional ectopic NFATc1-positive cells in the cushion mesenchyme. In serial sections, colocalized expression of NFATc1 transcript and protein is observed in cushion mesenchymal cells of RANKLtreated hearts compared to endocardial restricted expression in control hearts (Figs. 6C-F; arrows) . Sections from control or RANKL-treated hearts show low level Ctsk expression in the endocardium of outflow tract cushions (Figs. 6G, H; arrowheads) . In RANKL-treated hearts, endocardial cells with strong NFATc1 expression also show an increase in Ctsk expression relative to vehicle treated hearts (Figs. 6E-H) . Thus, RANKL can stimulate cardiac expression of NFATc1 and Ctsk during early stages of heart valve development, and the RANKL-mediated induction of Ctsk expression is dependent on NFATc1.
Discussion
During heart valve morphogenesis, remodeling of the primitive endocardial cushions into mature valve leaflets is critical for advanced heart development and function. This process requires calcineurin/NFATc1 signaling in the endocardium following EMT (Chang et al., 2004; de la Pompa et al., 1998; Ranger et al., 1998) , however, the regulatory pathways that govern NFATc1-dependent valve remodeling have not been defined. Studies which identified NFATc1 as a critical transcriptional regulator of bone remodeling enzymes such as Ctsk and TRAP during RANKL-mediated osteoclast differentiation provided insight into a signaling pathway by which NFATc1 regulates matrix remodeling events (Hirotani et al., 2004; Ikeda et al., 2004; Ishida et al., 2002; Matsumoto et al., 2004; Matsuo et al., 2004; Takayanagi et al., 2002) . Investigation of this signaling cascade during valvulogenesis shows that RANKL pathway genes are expressed in the remodeling heart valves, that RANKL and Ctsk expression in the valve endocardium is dependent on NFATc1, and that RANKL treatment can induce NFATc1 and Ctsk expression.
Despite the established requirement for calcineurin/NFATc1 signaling during heart valve development, the critical regulators of calcineurin activation and NFATc1 nuclear translocation during valve remodeling have not been well characterized. While VEGF can stimulate calcineurin-dependent NFATc1 nuclear translocation in cultured adult human pulmonary valve endothelial cells, it remains to be determined whether VEGF signaling can induce NFATc1 activation in the endocardium during embryonic heart valve remodeling (Johnson et al., 2003) . In this study, we find evidence that RANKL signaling is upstream of NFATc1 during heart valve remodeling. Interestingly, expression of RANKL in the developing valves is also dependent on NFATc1, indicating that RANKL expression is subject to feedback regulation by NFATc1. Although expression of RANKL during bone development is not affected by inhibition of calcineurin/NFATc signaling, induction of RANKL in activated T-cells is regulated by Ca 2+ signals and can be blocked by the calcineurin inhibitor cyclosporin A, consistent with calcineurin/NFATc-dependent regulation of RANKL expression (Koga et al., 2005; Wang et al., 2001 Wang et al., , 2002 . Thus, the interaction between RANKL and NFATc1 during heart valve development likely involves complex positive and negative feedback regulatory mechanisms.
Defining the exact functional requirements for NFATc1 during heart development has been limited by the lack of identified downstream target genes relevant to valve leaflet remodeling. Although NFATc1 is required for osteoclast differentiation and heart valve formation, the regulatory requirements for NFATc1 in each system are not the same. During osteoclast differentiation, PU.1 cooperates with NFATc1 to directly regulate Ctsk gene expression and NFATc1 directly activates the TRAP promoter (Matsumoto et al., 2004; Takayanagi et al., 2002) . However, PU.1 does not appear to contribute to endocardial expression of Ctsk and cells possessing TRAP enzymatic activity are not detected in the developing valves, indicating that NFATc1 does not promote TRAP expression during valve formation. Thus, there are distinct differences in the regulatory mechanisms that control Ctsk expression and promote TRAP expression in osteoclasts versus the valve endocardium. Notably, the results from the present study show that expression of Ctsk in the valve endocardium during stages of leaflet remodeling is dependent on NFATc1. In a poorly understood process during valvulogenesis, the primitive endocardial cushions are remodeled into thin valve leaflets that contain an organized extracellular matrix comprised primarily of collagen and elastin (Icardo and Colvee, 1995; Missirlis and Armeniades, 1977) . As collagen and elastin are substrates of Ctsk, it will be interesting to determine if Ctsk contributes to the remodeling and organization of these extracellular matrix components during heart valve maturation (Bossard et al., 1996; Garnero et al., 1998) .
Although the results of this study indicate that RANKL signaling and Ctsk are associated with valve remodeling in the embryonic heart, mice with targeted inactivation of RANKL, RANK, OPG, or Ctsk are viable and have no reported defects in valve formation (Bucay et al., 1998; Fata et al., 2000; Gowen et al., 1999; Kong et al., 1999; Li et al., 2000; Mizuno et al., 1998) . Since valve development in these mice is not as severely compromised as in NFATc1 −/− embryos, it is likely that additional signals are involved in activation of calcineurin/NFATc1 signaling in the valve endocardium. Furthermore, the lack of any reported valve anomalies in humans with pycnodysostosis, resulting from mutations in Ctsk, indicates that additional matrix remodeling enzymes likely contribute to proper leaflet formation (Gelb et al., 1996; Johnson et al., 1996) . Interestingly, mice with homozygous null mutation of TNF-α converting enzyme (TACE) have abnormal valve remodeling resulting in enlarged leaflets, and TACE has been implicated in the functional regulation of RANKL via proteolytic release from the plasma membrane (Horiuchi et al., 2005; Jackson et al., 2003; Lum et al., 1999) . In addition, calcineurin/NFATc1 signaling is activated in response to acidosis, and remodeling heart valves have endogenous acid phosphatase activity, indicating that acidification may also contribute to activation of calcineurin/NFATc1 signaling during valve remodeling (Komarova et al., 2005) . Thus, identifying the regulatory interactions between pathways that intersect with calcineurin/NFATc1 signaling in the valve endocardium will provide a better understanding of the molecular mechanisms that control valve leaflet remodeling.
The presence of the RANKL signaling pathway during heart valve development has provided new insight into a regulatory mechanism underlying NFATc1-dependent valve remodeling. Interestingly, the RANKL system has also been implicated in cellular remodeling events during calcification of the adult valves and vasculature (Collin-Osdoby, 2004; Kaden et al., 2004 Kaden et al., , 2005 Vattikuti and Towler, 2004) . However, further detailed mechanistic studies are necessary to define RANKL pathway function in relation to NFATc1 during valve leaflet formation as well as pathogenetic calcification processes. Malformations of the valves are common congenital heart defects, and recent studies indicate a genetic basis for valvular heart disease (Garg et al., 2005; Hoffman and Kaplan, 2002; Horne et al., 2004) . Therefore, defining the molecular mechanisms that govern valve leaflet formation has significant implications toward understanding the etiology of congenital valve anomalies as well as for adult valve disease.
